MPS Powered by Eureka

Current Psychopharmacology

ISSN: 2211-5560 (Print)
eISSN: 2211-5579 (Online)

Aims and Scope:Current Psychopharmacology publishes peer-reviewed expert reviews, original research articles and single topic guest edited issues on all aspects of pre-clinical and clinical research in psychopharmacology. The journal aims to be the leading forum for expert review articles in the field. The journal also accepts high-level original research articles on outstanding topics of preclinical and clinical psychopharmacology. Data must be published for the first time in Current Psychopharmacology.

Editor-in-Chief:


Kenneth Blum Department of Psychiatry
Western University Health Sciences
Pomona, CA
USA

Indexed in:


Cabell's Directory/Journalytics... View all

Special Issues With Active Call for Papers

Submission closes on: Feb 20, 2026
PD-1 Inhibitors in Neuroprotection: Modulating Neurotransmitter Pathways for Therapy

Programmed cell death protein-1 (PD-1) inhibitors, widely recognized for their role in immunotherapy, have recently emerged as potential neuroprotective agents. Beyond their traditional application in oncology, PD-1 inhibitors influence neuroimmune interactions, impacting neurotransmitter pathways critical for maintaining brain homeostasis. Dysregulation of these pathways is implicated in neurodegenerative and neuropsychiatric disorders, including Parkinson’s disease, Alzheimer’s disease, and depression. By modulating immune responses, PD-1 blockade may reduce neuroinflammation, enhance neuronal survival, and restore neurotransmitter balance. Recent studies... see more

Submission closes on: Dec 31, 2025
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders

Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the current pharmacotherapeutic approaches to treating mental illnesses as well as drug delivery approaches that have improved existing therapies. Approaches to improve drug bioavailability, provide controlled... see more